NCT00594308 · OUTCOME

Time to Resolution of Cytopenias: Platelet Transfusion Independence

In-Vivo Activated T-Cell Depletion to Prevent GVHD · Source last updated 2014-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: days per patient
Interval / dispersion: Standard Deviation
Time frame: From Day -1 (day before stem cell infusion) to Day +20 (20 days after stem cell infusion)

What was measured

Average number of days per patient for resolution of cytopenias.

Analysis population: IIT: All patients that received study drug.

All patients that received Basiliximab 20 mg monoclonal therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Basiliximab 20 mg	10

Source class 1

Values in days per patient · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Basiliximab 20 mg	15.33	3.54	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Average number of days per patient for resolution of cytopenias.

dispersion Type

Standard Deviation

groups

param Type

MEAN

population Description

IIT: All patients that received study drug.

time Frame

From Day -1 (day before stem cell infusion) to Day +20 (20 days after stem cell infusion)

title

Time to Resolution of Cytopenias: Platelet Transfusion Independence

type

SECONDARY

unit Of Measure

days per patient

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice